Thinking of taking your company public? Get our essential guide to a successful IPO. Download Now

Westicke Partners


William Blair and Westwicke to Host Biotechnology Pre-IPO Crossover Investor Conference on July 9

Chicago, Il. and Baltimore, Md., July 8, 2015 – William Blair, a global investment banking and asset management firm, and Westwicke, the largest healthcare-focused investor relations and IPO advisory firm in the country, announced today they are hosting a Biotechnology Pre-IPO Crossover Investor Conference. The conference will be held in New York on July 9, 2015 and will provide a forum for private biotechnology companies to meet and foster relationships with institutional investors.

“Combining our equity capitals markets expertise together with the investor relations capabilities at Westwicke, we are excited to host this event which connects high quality and innovative private biotechnology companies with market-leading institutional investors,” said Steve Maletzky, head of William Blair’s healthcare equity capital markets group. “As the demand for new equity issuances has increased, institutional investors are actively seeking to engage with private companies at earlier stages of the capital formation process. In many sectors this has given companies the ability to stay private longer; however, in biotechnology, pre-IPO financings have been the catalysts that drive more successful IPOs.”

“We are delighted to be partnering with William Blair to host this innovative and important conference,” said Bob East, Managing Partner, Westwicke. “Investors have the opportunity to interact with leading names in biotechnology, while the participating private companies gain access to funds that are actively putting money to work in the biotech sector. We stand ready to offer our services to these private firms as they plan for their future in the public company arena.”

Private companies expected to participate in the conference include Aileron Therapeutics, Inc., Alzheon, Inc., Avelas Biosciences, Inc., Formula Pharmaceuticals, Inc., Merus B.V., NeuroPhage Pharmaceuticals, Inc., Oryzon Genomics, S.A., PaxVax, Inc., Scholar Rock, Inc., and scPharmaceuticals, Inc.

About William Blair
William Blair is a global investment banking and asset management firm. We are committed to building enduring relationships with our clients and providing expertise and solutions to meet their evolving needs. An independent and employee-owned firm, William Blair is based in Chicago, with offices in 16 cities across five continents. For more information, please visit

About Westwicke
Westwicke provides customized strategic investor relations programs and independent capital markets advice to public and private healthcare companies. Westwicke focuses on the healthcare sector exclusively, and is headquartered in Baltimore with regional offices in San Diego, San Francisco and Boston. For more information, please visit


For William Blair:
Kristin Monroe

For Westwicke:
Tom McDonald

Have News to Release?

Find out whether you should file a Form 8-K, issue a press release, or do both by using our easy-to-reference chart, “Form 8K vs. Press Release: What’s the Difference?

Our Locations